Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study

María-Victoria Mateos,Miguel-Teodoro Hernández, Carlos Salvador,Javier de la Rubia, Felipe de Arriba,Lucía López-Corral,Laura Rosiñol,Bruno Paiva,Luis Palomera,Joan Bargay, Albert Oriol,Felipe Prosper,Javier López,José-María Arguiñano,Joan Bladé, Juan-José Lahuerta,Jesús San-Miguel

European Journal of Cancer（2022）

引用 0|浏览15

暂无评分

摘要

•High-risk smoldering presents a 50% progression risk to active myeloma at 2 years.•Early treatment has demonstrated to delay the progression to myeloma.•Rd confirms the sustained benefit in TTP and OS in high-risk smoldering.•Many trials are ongoing to support the role of early detection and intervention.

查看译文

关键词

Lenalidomide,Dexamethasone,Smoldering multiple myeloma,Drug therapy,Followup study

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要